How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
0 citations0 with PMIDValidation: 0%0 supporting / 0 opposing
✓For(0)
No supporting evidence
No opposing evidence
(0)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
No evidence recorded in matrix format.
Legacy Card View — expandable citation cards
✓ Supporting Evidence
0
No evidence recorded
✗ Opposing Evidence
0
No evidence recorded
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Price History
7d Trend
↘
Falling
7d Momentum
▼ 32.3%
Volatility
Low
0.0097
Events (7d)
6
Clinical Trials (0)
No clinical trials data available
📚 Cited Papers (0)
No linked papers yet
📅 Citation Freshness Audit
Freshness score = exp(-age×ln2/5): halves every 5 years.
Green >0.6,
Amber 0.3–0.6,
Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
Loading history…
⚖️ Governance History
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions,
Elo penalties, or pause grants affect this subject.
IF adults with rheumatoid arthritis receive experimental drug A at 10 mg daily for 8 weeks, THEN their Disease Activity Score 28 (DAS28) will decrease by at least 1.2 units compared to placebo within 8 weeks.
pendingconf: 0.50
Expected outcome: Mean DAS28 reduction ≥1.2 units in the treatment group.
Falsified by: No statistically significant difference in DAS28 change between treatment and placebo (p > 0.05) or reduction <1.2 units.
Method: Double‑blind randomized controlled trial (RCT) in 200 rheumatoid arthritis patients, with standardized DAS28 assessment at baseline and week 8.
IF rheumatoid arthritis patients are treated with escalating doses of drug A (5 mg, 10 mg, 20 mg daily) over 4 weeks, THEN serum levels of biomarker X will increase in a dose‑dependent manner, with the 20 mg group showing at least a 30% increase relative to baseline within 4 weeks.
pendingconf: 0.50
Expected outcome: ≥30% rise in serum biomarker X in the high‑dose group.
Falsified by: Absence of a dose‑response relationship; biomarker X increase <30% at any dose.
Method: Phase‑2 dose‑escalation cohort of 60 patients with serial biomarker measurements at baseline, week 2, and week 4.